Avalon Globocare (Avalon Globocare) Risk Assessment

View and export this data going back to 2016. Start your Free Trial

What is Avalon Globocare Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Avalon Globocare is: High Risk: High uncertainty.

Competitive Comparison of Avalon Globocare's Risk Assessment

For the Real Estate Services subindustry, Avalon Globocare's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalon Globocare's Risk Assessment Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, Avalon Globocare's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Avalon Globocare's Risk Assessment falls into.

Avalon Globocare (NAS:ALBT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Avalon Globocare Risk Assessment Related Terms

Thank you for viewing the detailed overview of Avalon Globocare's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalon Globocare (Avalon Globocare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Avalon Globocare Corp (NAS:ALBT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

4400 Route 9 South, Suite 3100, Freehold, NJ, USA, 07728

Website

https://www.avalon-globocare.com

Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. It has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.

Executives

Lourdes Felix	director	15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
W J Tauzin	director	901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508
Wenzhao Lu	director, 10 percent owner	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Andrew Sanders	director	431 EAST 20TH STREET, NEW YORK NY 10010
Yancen Lu	director	14009 SE 50TH STREET, BELLEVUE WA 98006
Stilley William B. Iii	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Tevi Troy	director	611 SOMERSWORTH WAY, SILVER SPRING MD 20902
Luisa Ingargiola	officer: Chief Financial Officer	4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
David Jin	director, officer: CEO and President	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Yue Charles Li	director	C/O AVALON GLOBOCARE CORP., 4400 ROUTE 9 SOUTH, SUITE 3100, FREEHOLD NJ 07728
Meng Li	director, officer: Chief Operating Officer	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Philip Sukel	director	33 ALPINE DRIVE, MORGANVILLE NJ 07751